Sumitomo Pharma Co., Ltd. (4506.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Sumitomo Pharma Co., Ltd.
Address
6-8 Doshomachi 2-chome
Osaka, 541-0045
Japan
Phone
81 6 6203 5321
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4980
First IPO Date
January 04, 2000
Key Executives
| Name | Title | Pay | Year Born |
| Toru Kimura | Representative Director, President & Chief Executive Officer | 101M | 1960 |
| Koji Yamazaki | Exec. Off. of Sales & Mark. Div., SVP, Hd. of Sales & Mark. Div. Dep. Hd. of Japan Bus. Unit | 0 | N/A |
| Hideyuki Harada | Mng. Exe. Off. of Supply Chain Div., SVP, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit | 0 | N/A |
| Motoyuki Sakai | EVP of Global Corp. Strategy, Fin. Admin, Ex. Aff., CG, Corp. Comm.; IT Mgmt & DA & Rep. Director | 0 | 1961 |
| Kimihiro Mizuno | Executive Officer Legal & Compliance and Intellectual Property | 0 | N/A |
| Kenji Ueno | Executive Officer, Senior Vice President and Deputy Head of Research and Development Division (CMC) | 0 | N/A |
| Koichi Kozuki | E.O. of Corp. Reg. Comp., Bus Dev mgmt & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div & Dp. Hd of Jap. Bus. | 0 | N/A |
| Yumi Sato | Managing Exe. Officer of Research & Dev. Div. Senior Vice President and Head of Research & Development Division | 0 | N/A |
| Tsutomu Nakagawa | Managing Executive Officer & Director | 0 | 1968 |
| Megumi Maruyama | Vice President & Head of Corporate Communications | 0 | N/A |
| Katsuhiko Nishida | EO, SVP of S&M & Head of Japan BU Deputy | 0 | N/A |
| Isao Shimizu | Exec. Off.,SVP, Dep. Head of R&D Div. & Corp. Reg.Comp & Quality Assurace. Div. | 0 | N/A |
| Shunji Kobayashi | Executive Officer of Human Resources | 0 | N/A |
Description
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
